FindTrial
Sign In

Effectiveness of Chinese herbal medicine as a complementary treatment for neutropenia prevention and immunity modulation during chemotherapy in patients with breast cancer: a real-world pragmatic clinical trial

Effectiveness of Chinese herbal medicine as a complementary treatment for neutropenia prevention and immunity modulation during chemotherapy in patients with breast cancer: a real-world pragmatic clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2023000054
Enrollment
Unknown
Registered
2023-10-18
Start date
2021-09-16
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

CHM:Chemotherapy+CHM
Control:Chemotherapy only

Sponsors

National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taiwan
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients aged more than 20 years, with a histologically confirmed diagnosis of breast cancer before the initiation of chemotherapy, are considered eligible for this study.

Exclusion criteria

Exclusion criteria: Patients who will not be able to finish the chemotherapy and follow-up procedures, those who receive other medication, and those with an Eastern Cooperative Oncology Group (ECOG) score of 3–4 will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
Profile of immune cells;—

Secondary

MeasureTime frame
WBC count;Frequency of G-CSF inoculation;Questionnaire;Neutrophil count;—

Countries

China

Contacts

Public ContactChi-Cheng Li

Hualein Tzu Chi Hospital

kevinlcc1234@gmail.com0911363713

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 7, 2026